Bessette, Louis http://orcid.org/0000-0002-6834-2731
Chan, Jonathan http://orcid.org/0000-0002-1837-5340
Chow, Andrew http://orcid.org/0000-0002-9907-2949
Lisnevskaia, Larissa http://orcid.org/0000-0003-0897-3539
Richard, Nicolas http://orcid.org/0000-0003-3683-8713
Fournier, Pierre-Andre
Liazoghli, Dalinda http://orcid.org/0009-0000-0319-6131
Girard, Tanya
Haaland, Derek http://orcid.org/0000-0002-5959-956X
Clinical trials referenced in this document:
Documents that mention this clinical trial
Real-World Effectiveness of Upadacitinib for Treatment of Rheumatoid Arthritis in Canadian Patients: Interim Results from the Prospective Observational CLOSE-UP Study
https://doi.org/10.1007/s40744-024-00651-8
Funding for this research was provided by:
AbbVie Canada
Article History
Received: 17 December 2023
Accepted: 6 February 2024
First Online: 11 March 2024
Declarations
:
: Louis Bessette reports consultancies, research grants, and speaker fees from BMS, Janssen, UCB, AbbVie, Pfizer, Sanofi, Lilly, and Novartis; research grants and speaker fees from Sandoz, Fresnius Kabi, Teva, Organon, and JAMP Pharma; and research grants from Gilead. Jonathan Chan reports consultancy and/or speaker fees and research grants from AbbVie, Pfizer, and UCB, and consultancy and/or speaker fees from Amgen, Celgene, Janssen, Novartis, Roche, Gilead, Eli Lilly, Merck, Fresenius Kabi, and Sandoz. Andrew Chow reports consultancies, research grants, and speaker fees from Abbvie, Amgen, AstraZeneca, BioJamp, Celltrion, Eli Lilly, Fresenius Kabi, Janssen, Novartis, Pfizer, UCB. Larissa Lisnevskaia has no conflicts to report. Nicolas Richard reports consultancies and/or speaker fees from Abbvie, Amgen, AstraZeneca, Eli Lilly, Janssen, Novartis, Pfizer and UCB. Pierre-Andre Fournier, Dalinda Liazoghli and Tanya Girard are employees of AbbVie Corporation. Derek Haaland reports honouraria from Abbvie, Amgen, AstraZeneca, Bristol-Myers Squibb, Eli Lilly, GlaxoSmithKline, Janssen, Merck, Novartis, Pfizer, Roche, Sanofi-Genzyme, Takeda, UCB; advisory board or speakersā bureau membership for Abbvie, Amgen, AstraZeneca, Bristol-Myers Squibb, Eli Lilly, GlaxoSmithKline, Janssen, Novartis, Pfizer, Roche, Sanofi Genzyme, Takeda; research funding from Abbvie, Adiga Life Sciences, Amgen, AstraZeneca, Bristol-Myers Squibb, Can-Fite Biopharma, Celgene, Eli Lilly, Gilead, GlaxoSmithKline, Janssen, Novartis, Pfizer, Regeneron, Sanofi-Genzyme, and UCB.
: The study is conducted in accordance with the Declaration of Helsinki and International Conference on Harmonisation Guidelines for Good Clinical Practice. Institutional review board/independent ethics committee approval was obtained for all participating centres (TableĀ InternalRef removed in the Supplementary Material). All patients provided informed consent to participate in the study.